“The Liver-Chip detected nearly 7 out of every 8 drugs that proved hepatoxic in clinical use despite having been deemed to have an appropriate therapeutic window by animal models.”
The acquisition expands Veranex’s European footprint as well as the scale and scope of its clinical studies capabilities.
No longer just “the big company advantage,” CM&S is an accepted and viable device industry path to market for large and small medical device makers alike.
Across our industry, IoMT will enable us to conduct research in ways that would never previously have been possible.
While companies developing solutions that address the current pandemic may be receiving an influx of financial support, recovery for companies in other segments of the industry is slow.
Within this large and growing market, some companies are capitalizing, while others are faltering.